Effects of mosapride on esophageal functions and gastroesophageal reflux.
OBJECTIVE
A substantial number of patients with gastroesophageal reflux disease show symptomatic resistance to high-dose proton pump inhibitors. In those cases, prokinetics are possible candidates for treatment. The aim of the present study was to determine whether mosapride, a prokinetic agent, stimulates esophageal functions, and prevents acidic and non-acidic gastroesophageal reflux.


METHODS
Normal volunteers (nine and 13 for two experiments, respectively) were enrolled. Salivary secretion, esophageal peristaltic contractions, and resting lower esophageal sphincter pressure with and without mosapride administration were recorded using a cross-over protocol. Post-prandial acidic and non-acidic reflux levels were also recorded.


RESULTS
Mosapride at a standard dose of 15 mg/day did not stimulate salivary secretion or any esophageal motor functions. It also failed to prevent acidic and non-acidic post-prandial gastroesophageal reflux.


CONCLUSIONS
Mosapride at 15 mg/day, a standard dose in Japan, did not change the esophageal motility and salivary secretion in healthy volunteers. Future study on a larger number of individuals with higher dose of mosapride is worthwhile.
Koshino
Kenji
K
Second Department of Internal Medicine, Shimane University Faculty of Medicine, Shimane, Japan.
Adachi
Kyoichi
K
Furuta
Kenji
K
Ohara
Shunji
S
Morita
Terumi
T
Nakata
Shuji
S
Tanimura
Takashi
T
Miki
Masaharu
M
Kinoshita
Yoshikazu
Y
D000328:Adult; D000897:Anti-Ulcer Agents; D001549:Benzamides / Q000008:administration & dosage*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D017097:Electric Impedance; D049630:Esophageal Sphincter, Lower / Q000187:drug effects / Q000503:physiopathology; D050782:Esophageal pH Monitoring; D004947:Esophagus / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D005500:Follow-Up Studies; D005764:Gastroesophageal Reflux / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008365:Manometry; D009025:Morpholines / Q000008:administration & dosage*; D010528:Peristalsis / Q000187:drug effects / Q000502:physiology*; D011312:Pressure; D011379:Prognosis; D012016:Reference Values; D012463:Saliva / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage*
D000897:Anti-Ulcer Agents; D001549:Benzamides; D009025:Morpholines; D017366:Serotonin Receptor Agonists; C062720:mosapride